Data gathered: December 22
AI Stock Analysis - Castle Biosciences (CSTL)
Analysis generated October 25, 2024. Powered by Chat GPT.
Castle Biosciences, Inc. (NASDAQ: CSTL) is a notable player in the personalized cancer diagnostics sector. The company focuses on developing and commercializing diagnostic and prognostic tests for cancers, which provide clinicians with individualized treatment information, aiding them in making more informed decisions. Castle Biosciences aims to revolutionize the treatment landscape by ensuring that patients receive the most effective therapies tailored to their specific conditions.
Stock Alerts - Castle Biosciences (CSTL)
 |
Castle Biosciences | December 20 Insider Alert: MAETZOLD DEREK J is continuing selling shares |
|
Castle Biosciences | December 18 Price is down by -5.8% in the last 24h. |
|
Castle Biosciences | December 18 Insider Alert: MAETZOLD DEREK J is continuing selling shares |
|
Castle Biosciences | December 12 Price is up by 6.9% in the last 24h. |
Alternative Data for Castle Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 7 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 21,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 34 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 31 | Sign up | Sign up | Sign up |
| Facebook Followers | 692 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,013 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 987 | Sign up | Sign up | Sign up |
| Twitter Followers | 712 | Sign up | Sign up | Sign up |
| Twitter Mentions | 17 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 454 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 75 | Sign up | Sign up | Sign up |
| Linkedin Employees | 570 | Sign up | Sign up | Sign up |
About Castle Biosciences
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions.
| Price | $27.53 |
| Target Price | Sign up |
| Volume | 382,570 |
| Market Cap | $771M |
| Year Range | $17.4 - $34.67 |
| Dividend Yield | 0% |
| PE Ratio | 131.1 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Castle Biosciences Reports Inducement Grants under Nasdaq Listing Rule 5635(4)December 19 - Finnhub |
|
 |
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 18 - Yahoo |
 |
Castle Biosciences CEO Derek Maetzold sells $750,296 in stockDecember 17 - Investing.com |
 |
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCDecember 17 - ETF Daily News |
|
Janus Henderson Group PLC Invests $261,000 in Castle Biosciences, Inc. (NASDAQ:CSTL)December 16 - ETF Daily News |
|
Captrust Financial Advisors Cuts Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)December 16 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 86M | 16M | 70M | 2.3M | 11M | 0.080 |
| Q2 '24 | 87M | 15M | 72M | 8.9M | 10M | 0.310 |
| Q1 '24 | 73M | 14M | 59M | -2.5M | -230,000 | -0.090 |
| Q4 '23 | 66M | 12M | 54M | -2.6M | -130,000 | -0.100 |
| Q3 '23 | 61M | 11M | 50M | -6.9M | -4.6M | -0.260 |
Insider Transactions View All
| MAETZOLD DEREK J filed to sell 84,762 shares at $28.8. December 19 '24 |
| MAETZOLD DEREK J filed to sell 84,874 shares at $28.3. December 19 '24 |
| MAETZOLD DEREK J filed to sell 94,126 shares at $28.8. December 17 '24 |
| MAETZOLD DEREK J filed to sell 5,702 shares at $29.2. December 17 '24 |
| MAETZOLD DEREK J filed to sell 5,739 shares at $28.5. December 17 '24 |
Similar companies
Read more about Castle Biosciences (CSTL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Castle Biosciences?
The Market Cap of Castle Biosciences is $771M.
What is Castle Biosciences' PE Ratio?
As of today, Castle Biosciences' PE (Price to Earnings) ratio is 131.1.
What is the current stock price of Castle Biosciences?
Currently, the price of one share of Castle Biosciences stock is $27.53.
How can I analyze the CSTL stock price chart for investment decisions?
The CSTL stock price chart above provides a comprehensive visual representation of Castle Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Castle Biosciences shares. Our platform offers an up-to-date CSTL stock price chart, along with technical data analysis and alternative data insights.
Does CSTL offer dividends to its shareholders?
As of our latest update, Castle Biosciences (CSTL) does not offer dividends to its shareholders. Investors interested in Castle Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Castle Biosciences?
Some of the similar stocks of Castle Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.